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Abstract 11 
Breast cancer is the most common cancer diagnosed among reproductive aged women, and its 12 
treatment can compromise future fertility. Options for fertility preservation include oocyte or 13 
embryo cryopreservation after ovarian stimulation (OS), which are the most established 14 
choices and are applicable for adult women with cancer. Ovarian tissue freezing may also be 15 
appropriate, as it offers potentially the least delay. The recognistion of the role of BRCA1 and 16 
BRCA2 mutations in some women has led to the involvement of preimplantation genetic 17 
diagnosis (PGD), recently renamed preimplantation genetic testing for monogenic disorder 18 
(PGT-M), whereby embryos are created by IVF and cell(s) are removed and genetically 19 
analyzed for specific disease-related mutations. PGT-M offers a valid option for women 20 
wishing to avoid transmission of the predisposition for hereditary breast cancer to their 21 
offspring. The aim of this paper is to provide an overview of the factors that influence fertility 22 
preservation in newly diagnosed breast cancer patients, and to illustrate the option of PGT-M 23 
to enable conception of an unaffected child. 24 
 25 
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 28 
Background  29 
Breast cancer (BC) is the most common cancer in women of reproductive age, with more than 10% 30 
of new cases diagnosed in women younger than the age of 40 years [41]. Currently, with the social 31 
trend to delaying motherhood until later in life, there are an increasing number of women who have 32 
not completed childbearing at the time of cancer diagnosis, and therefore are likely to desire 33 
pregnancy following the chemotherapy [56]. In 2018, has been calculated that 2.1 million new cases 34 
of BC were diagnosed worldwide [12]. For many years, BC has been considered the most important 35 
cancer in reproductively-aged women, both in terms of incidence and mortality. However, for a 36 
range of reasons including improved screening methods and therapies, the number of deaths has 37 
been decreasing. Whereas in 2009, estimated deaths were 21.1% of estimated new cases, they were 38 
15.4% in 2018, with a reduction of 27% over the last decade [22]. However, a potential side effect 39 
is the loss of fertility or impaired reproductive function [81]. Additionally, women with hormone 40 
receptor positive disease may also be advised to take hormonal therapy for up to 10 years after 41 
chemotherapy. This, also impact on the complexity of reproductive choices they have to make, 42 
facing declining fertility through increasing age as well as from effects of chemotheraphy. Fertility 43 
concerns among young cancer patients have an important role in determining quality of life [69]. At 44 
the time diagnosis, about half of young women are concerned about becoming infertile or having 45 
reduced reproductive function after BC treatment, ad while a survey 5 years ago indicated that 46 
only a small minority of 10% take up fertility preservation (FP) options [80], this proportion is 47 
increasing. There have also been concerns about whether a subsequent pregnancy may increase the 48 
chance of recurrence of breast cancer, but it is now clear that this is not the case [44].  49 
 50 
Fertility Preservation: Available Options  51 
The many advances in assisted reproductive technologies (ART) over the forty years since its 52 
introduction include the development of methods and strategies for FP in women with BC and other 53 
conditions whose treatment risks their future fertility, before initiation of anti-cancer therapy. These 54 
include cryopreservation of oocytes or embryos after OS, or ovarian tissue cryopreservation (OTC) 55 
[3, 27]. The recognition of the role of mutations i the BRCA1 and BRCA2 genes in the aetiology 56 
of breast and other cancers in some women also intrduces consideration of the use of PGT-M in 57 
women with these genetic mutations in order to avoid transmitting the mutation to their offspring. 58 
These considerations have raised some concerns, but the possible health and psychological 59 
consequences of this particular condition are considered to justify its use [86]. These complex 60 
issues will be occurring at a time of great stress and uncertainty to patients in the immediate 61 
aftermath of a new diagnosis. This and the very limited time available for discussion, decisions and 62 
potential interventions requires excellent lines of c mmunication between the oncology setting and 63 
reproductive medicine. This review discusses the avail ble methods for FP in women with breast 64 
cancer, and the role of PGT-M in this context. Protection of the ovary from chemotherapy-induced 65 
damage has also been the subject of significant investigation. This has recently been reviewed by 66 
Spears and colleagues [87], but of particular importance to women with breast cancer is the 67 
demonstration, now confirmed in several large RCTs, that administration of GnRH agonists during 68 
chemotherapy for breast cancer reduces the risk of premature ovarian insufficiency (POI). This has 69 
been subject to recent meta-analysis [45], thus will not be discussed in detail here. However it is 70 
important to recognize that while there seems good evi ence regarding risk of POI, whether there is 71 
an increased chance of a subsequent pregnancy is unclear, and this approach should not be regarded 72 
as an effective form of FP where other interventions are possible. 73 
 74 
Risks to fertility in breast cancer patients  75 
Advances in chemotherapy and anti-cancer treatment have resulted in higher survival rates among 76 
cancer patients. The most common malignancy in adult women is breast cancer, affecting one in 77 
nine women [88]: the five-year survival rate for women treated for breast cancer in the UK is more 78 
than 80% [63]. Unfortunately, a side effect of chemotherapeutic drugs is the risk of developing POI, 79 
which is dependent on various factors. Most important is the chemotherapy regimen used and the 80 
drug doses: the alkylating agents are particularly gonadotoxic, but taxanes also have a negative 81 
effect [51]. The age of the patient is also important, s older women have a much higher reported 82 
incidence of POI after treatment, compared to the younger women [70, 49]. It is also clear that pre-83 
chemotherapy ovarian reserve, as reflecting in serum concentrations of anti-Mullerian hormone 84 
(AMH) are also predictive of long-term ovarian function. This has been demonstrated in several 85 
prospective studies in women with BC [6, 7] also showing the interaction with age [89]. 86 
Pretreatment antral follicle count (AFC) may also be predictive, but there are few data clarifying 87 
this [90]. 88 
 89 
 90 
 91 
Effect of chemotherapy 92 
Chemotherapy can have two different effects on ovarian function. The first is immediate, during or 93 
following the treatment, with loss of the growing follicle population resulting in amenorrhea. 94 
However, if sufficient primordial follicles remain in the resting pool upon the cessation of 95 
treatment, the population of growing follicles will then be restored, and menses resume. In contrast, 96 
the second is a longer term effect, caused by the depletion of the primordial follicle pool, and results 97 
in a shortened reproductive lifespan and POI. If there is only partial loss of primordial follicles, this 98 
longer term effect may not manifest itself until years following treatment [58]. Where the reduction 99 
in the primordial follicle pool is near complete, the effect is acute, and the patient undergoes 100 
immediate POI [70]. This results from the primordial pool of follicles being formed before birth, 101 
such that at birth, the ovary has a fixed amount of oocytes. Primordial follicles are continuously 102 
recruited out of the resting pool and activated to gr w, but from each cohort of this follicles, only 103 
very few will go to through to the pre-ovulatory stage and eventually only one will ovulate: the 104 
majority of follicles become atretic and will die at some point during development [36]. 105 
Chemotherapeutic agents can directly affect the resting pool of primordial follicles or the growing 106 
follicles. The loss of the growing population of follicles may lead to increased activation of 107 
primordial follicles and so the accelerated loss of that reserve. Chemotherapeutic agents target not 108 
only the germ cells, but also the somatic cells. Granulosa cells surround the oocyte proliferate 109 
during follicle maturation. Given the essential nature of the contact and communication between the 110 
oocyte and the granulosa cells, damage to granulosa cells will result in indirect damage to the 111 
oocyte, leading to follicle loss (Figure 1) [58]. 112 
It is difficult to predict the exact risk for future fertility. A population-based analysis of pregnancy 113 
after cancer showed that women with breast cancer diagnosis before the age of 40 had a markedly 114 
reduced chance of post-cancer pregnancy compared to age-matched controls, with a standardized 115 
incidence ratio of 0.39 (95% confidence interval 0.36-0.42), but also that there have been significant 116 
improvements in the chances of a post-cancer pregnancy over recent years (Figure 2) [4]. As stated 117 
earlier, the gonadotoxic effect of chemotherapy is directly associated to female age at the time of 118 
treatment and depends considerably on the agent used and the duration of treatment [51, 55]. With 119 
reference to agents commonly used for breast cancer, alkylating agents have the strongest 120 
gonadotoxic potential. These agents, directly affect cell proliferation and primordial follicles [9], 121 
and promote cell apoptosis and follicle depletion [55]. Cyclophosphamide is one of the most 122 
effective drugs used for BC, is also the one of the most investigated compound in connection with 123 
gonadal toxicity: the risk of amenorrhea is high, and there is a four-fold higher risk of developing 124 
POI as compared with other agents [48, 51]. A high r sk of amenorrhea, particularly in women in 125 
their later reproductive years, is also associated with other drugs such as fluorouracil, epirubicin and 126 
fluorouracixorubicin, which are often used in women with breast cancer. Taxanes cause an 127 
intermediate ovarian damage, whereas methotrexate and 5-fluorouracil are associated with a lower 128 
toxicity risk [25, 48]. Limited clinical data are currently available regarding newer agents such as 129 
trastuzumab, bevacizumab, and cetuximab [91]. Abusief and colleagues [29] suggested that 130 
trastuzumab might not induce amenorrhea in premenopausal women with breast cancer. However, 131 
further studies are needed to clarify the effect of these agents on ovarian function.  132 
 133 
Oocyte Cryopreservation: from slow-freezing protocol 134 
 135 
In the last decades, the cryopreservation of mature oocyte has become an established procedure in 136 
ART, and represents a safe and effective method for patients wishing to preserve their fertility [64, 137 
97]. Oocyte quality is one of the most important factor influencing the vitrification-warming 138 
survival rate, and the subsequent fertilization and embryo development [31]. Cryopreservation 139 
involves freezing cells and subsequent storage in liquid nitrogen or its vapour at -196 °C. The first 140 
birth from a cryopreserved oocyte was reported in Australia in 1986, using a slow-freezing 141 
procedure [16]. Oocytes are extremely difficult cells to freeze successfully, mainly due to the large 142 
size cell, and the high content of water which during the freezing process might be converted to 143 
intracellular ice, which can induce damage and cell d ath [68]. Early studies highlighted difficulties 144 
in predicting the membrane permeability characteristics of human oocytes along with other 145 
biophysical components [29]. Several studies reportd the negative effects of cryopreservation on 146 
the stability of microtubules and the spindle in mammalian oocytes [72]. In addition, zona pellucida 147 
(ZP) hardening after cryopreservation was reported as an extra complication from the freezing 148 
process [97] although this can be overcome by the use of intracytoplasmic sperm injection (ICSI) 149 
[73]. Other possible injuries resulting from cooling and warming procedures include DNA 150 
fragmentation [33], damage to intracellular organelles [38] and epigenetic risks [99].  151 
 152 
To Vitrification  153 
A massive breakthrough in ART cryopreservation was reported with the introduction of 154 
“vitrification” in the late 1990s [43]. Vitrification was proposed as an alternative to the slow-155 
freezing technique for human oocytes and embryos and was expected to give superior success rates 156 
in term of cryo-survival and pregnancy outcomes. The Human Fertilisation and Embryology 157 
Authority (HFEA) has allowed the use of frozen oocytes for infertility treatment in the UK since 158 
2000 [98] and the American Society for Reproductive M dicine (ASRM) in 2013 removed the 159 
experimental label applied to oocyte freezing [74] following randomized controlled studies [18, 77] 160 
which reported that IVF using vitrified-warmed oocytes could produce similar pregnancy outcomes 161 
to IVF with fresh oocytes. A recent meta-analysis confirmed that results from vitrification are 162 
superior to those achieved with slow freeing protocls [78]. An important consideration to make is 163 
the choice of the carrier used for vitrification, esp cially in terms of whether liquid nitrogen comes 164 
in contact with the droplet containing the embryo (open vitrification) or not (closed vitrification). 165 
The issue with open vitrification is that liquid nitrogen itself can contain microbes or pathogens, 166 
therefore concerns have been raised over the sterility of open systems due to potential cross 167 
contamination between the vitrification sample and liquid nitrogen [10]. Published studies have 168 
shown that closed vitrification devices can be used for successful cryopreservation of human 169 
embryos [82, 83, 96]. While some IVF scientists remain concerned that closed systems may reduce 170 
the survival rates, in the UK 75% of clinics use closed rather than open devices for vitrification 171 
[13].    172 
 173 
Oocyte cyopreservation in cancer patients  174 
The developments in oocyte cryopreservation described above can be considered a major advance 175 
in FP. Prior to the development of vitrification, slow freezing of oocytes had a very low success 176 
rate, and the more effective option of embryo cryopeservation was only available to women with a 177 
partner, other than with the use of donated sperm. Cryopreservation of immature oocytes with 178 
subsequent in vitro maturation is a potential option but still considered experimental [47], thus in 179 
this section cryopreservation of mature oocytes (ie at metaphase II, MII) only will be discussed. A 180 
key aspect of this approach is the need for OS, which takes at least 2 weeks, despite the 181 
development of ‘random start’ protocols to minimise d lay.  These involve the administration of 182 
FSH to stimulate multi-follicular development, whic an be started at any stage in the menstrual 183 
cycle, with co-administration of GnRH antagonists to prevent premature ovulation [23]. In general, 184 
women with breast cancer respond to OS with the number of mature oocytes collected that would 185 
be expected based on their age and pretreatment ovarian ssessment [75]. Exposure to 186 
supraphysiological levels of estrogen as a result of OS, albeit briefly, may be a particular risk for 187 
patients with a hormone receptive cancer, and the arom tase inhibitor letrozole is widely used to 188 
minimise this [94] without apparent detrimental effect on the ovarian response or the quality of the 189 
oocytes recovered. Oktay and co-workers [64] analyzed the efficacy of oocyte cryopreservation by 190 
vitrification in a meta-analysis, and reported live birth rates per oocyte warmed of 6.6%. A recent 191 
study investigated the pregnancy outcome in fertility preservation after oocyte freezing for age-192 
related fertility decline and for patients before can er treatment. This showed that overall oocyte 193 
survival was comparable between the two groups, but implantation, ongoing pregnancy and live 194 
birth rates were lower in cancer patients [20]. A live birth rate of 61.9% was reported from 12 195 
cryopreserved oocytes in women ≤35 years and of 43.4% from 10 oocytes in those >35 years, illustrating the 196 
importance of both the number of oocytes that can be collected and cryopreserved (which of course declin s 197 
with age), and the decline in oocyte quality with age. Another aspect to be mentioned is the ideal 198 
number of oocytes to freeze in order to obtain a pregnancy after warming. This is a critical point 199 
that could be very useful and help clinicians to inform correctely their patients and plan their 200 
treatments accordingly [34]. This aspect was investigated in a recent multicenter retrospective 201 
study, incluted a total on 6,362 women who underwent to oocyte vitrification for FP, due to age-202 
related fertility decline (5,289 women) or for oncological reasons (1,172 women). The authors 203 
reported an increased cumulative live birth rate from 15,8% with 5 oocytes to 32.0% with 8 204 
oocytes. For younger patients (≤ 35 years old) 10 or 15 oocytes provided success rate of 42.8% and 205 
69.8%. The highest cumulative live birth rate of 94.4% was obtained in younger patients when 206 
number of oocytes vitrified was 24 [20]. Another study, evaluated the minimum number of mature 207 
oocytes to achieve at least one euploid blastocyst for transfer. The study found that the age of the 208 
woman was the most critical predictor for the likelhood of achieving one euploid blastocyst. Based 209 
on this model a patient of 37 years-old undergoing ART treatment using ejaculated sperm needs 210 
between 9 to 13 mature oocytes to obtain at least one euploid blastocyst to transfer [28]. Regarding 211 
the safety of the procedure, studies have analyzed th  long term obstetric and perinatal outcomes 212 
associated with oocyte vitrification. An analysis of 165 pregnancies and 200 infants found that the 213 
mean birth weight and incidence of congenital abnormalities were similar in infants born following 214 
oocyte vitrification to those born from spontaneous conception or through standard ART treatment 215 
[17]. Another review of 936 infants, born following either slow-freezing or vitrification of oocytes, 216 
also reported a comparable incidence of congenital abnormalities [61]. A large study published in 217 
2014 reported births of 1027 babies derived from vitrified-warmed oocytes and suggested that 218 
oocyte vitrification does not increase adverse obstetric and perinatal outcomes [19]. Thus, clinical 219 
outcomes using vitrified-warmed oocytes followed by IVF or ICSI appear to be similar to outcomes 220 
using fresh oocytes. However, these data were mainly reported for oocyte donation cycles and for 221 
standard ART cycles. Comparable data for women after cancer treatment who became pregnant and 222 
delivered a child after oocyte cryopreservation are not yet available.  223 
 224 
Embryo cryopreservation in cancer patients 225 
Oocytes obtained from OS can be fertilized using the partner’s sperm, and cryopreserved for future 226 
use. The first pregnancy from cryopreserved embryos was reported in Australia in 1983 [93] and the 227 
first baby born after transfer of a cropreserved-thawed blastocyst was announced in 1985 [21]. 228 
Initially, slow-freezing was the method used, but as with oocytes, this has now been replaced by 229 
vitrification. Embryo cryopreservation is the most e ablished FP option for BC patients who have a 230 
male partner [39, 40] or for those women who are using donor sperm. Although this option is the 231 
most widely used globally, is not an option for couples who might have personal religious or moral 232 
objections. In addition, it is essential that the patient is informed and recognizes that any such 233 
embryos will require consent from both her and her partner for their subsequent use, and that may 234 
be problematical if the relationship is not continuing at the time of use [48]. Embryo 235 
cryopreservation implies OS: as described above, recently studies have reported the use of OS 236 
protocols that can be started at anytime during the menstrual cycle [23]. Comparison of patients 237 
with and without cancer who underwent IVF and embryo cryopreservation have shown no 238 
difference in the number of collected oocytes, fertilization rates and number of live births, although 239 
patients with cancer had fewer good quality embryos [64]. Published studies have reported 240 
pregnancy outcomes comparable to those of non-oncolgi al populations after IVF. Muñoz and 241 
collaborators performed a cohort study including 259 patients with early BC scheduled to receive 242 
chemotherapy (age 18 to 40 years old) divided into patients who wished to preserve their fertility 243 
(exposed group; n = 148), and underwent OS and chose to vitrify their oocytes, and patients with 244 
the same characteristics, but who did not want to preserve their fertility (non-exposed group; 245 
n = 111). The primary endpoint was disease free survival time and overall survival rate, with a 246 
follow-up of 5 years. Recurrences occurred in 9/148 women (6.1%) in the exposed group and 247 
15/111 women (13.5%) in the non-exposed group, with no significant difference. The overall 248 
survival rates were comparable: 2/148 (1.4%) and 4/111 (3.6%) patients died, in exposed and non-249 
exposed groups, respectively, therefore the authors c ncluted that ovarian stimulation in patients 250 
with early stage breast cancer appears safe in the long term [59]. A study published by Oktay and 251 
coauthors analysed OS with the concurrent use of letr zole in 131 women with BC with the purpose 252 
of FP via embryo freezing. Of the 131 women undergoing embryo cryopreservation, 33 come back 253 
to thaw their embryo and use in frozen embryo transfers. Post thaw survival rate of embryos was 98 254 
(84.4%) and the mean number of embryos transferred was 1.97 ± 0.7. They reported an overall 255 
clinical pregnancy per transfer of 65.0% (26 of 40), live birth per transfer of 45.0% (18 of 40), 256 
which is comparable to those in a non-cancer population undergoing ART treatment [66]. Table 1 257 
displays published trials performed to assess ovarian performance in cancer, in which breast cancer 258 
disease was a predominant diagnosis. 259 
 260 
 261 
Ovarian Tissue Cryopreservation (OTC) 262 
OTC is a potential option for young women with breast cancer, though relatively infrequently used 263 
where oocyte vitrification is available. Although tere are historic reports of ovarian transplantation 264 
in humans [62], the technique came to the fore following its successful development in the sheep, 265 
where ovarian function and fertility were demonstrated after cryopreservation and 266 
autotransplantation of ovarian cortical tissue [8, 32]. The first live birth was annouced in 2004 [27], 267 
and now more than 130 live births have been reported worldwide [30], demonstrating that this 268 
strategy is viable in adults, although the success rate is unclear because the total number of attempts 269 
performed is unknown. OTC involves the surgical removal (or dissection following oophorectomy 270 
in many cases) and cryopreservation of the ovarian cortex. Later, upon completion of oncologic 271 
treatment, the ovarian tissue can be thawed and transpl nted back into the patient, either to 272 
orthotopic (into the pelvic cavity; on the atrophic ovary) or heterotopic sites (outside of the pelvis; 273 
subcutaneous regions such as the forearm) although nly limited success has been reported from the 274 
latter. It can be performed at any time during the m nstrual cycle, there is no need for OS, and 275 
therefore no delay in cancer treatment, and it results in storage of a large number of primordial 276 
follicles, depending on the patient’s age [27]. After reimplantation, ovarian function is expected to 277 
be restored after 4-5 months, normally in more than 90% of patients. Regarding the freezing 278 
procedure, slow freezing is most widely used: most centres use Gosden’s protocol with 279 
dimethylsulfoxide [60]. The efficiency of vitrification for freezing human ovarian tissue remains 280 
controversial [1] but there have been two reports of births from vitrified and replaced ovarian tissue 281 
[30]. Ovarian graft longevity is very variable but the woman’s age is a crucial factor in determining 282 
success, and many centres use an upper age limit of 35 years, in addition to criteria regarding risk of 283 
infertility and chance of survival [3, 27]. Although, more than 130 live births have been reported 284 
worldwide [30], there are still unresolved concerns, a  substantial loss of primordial follicles is 285 
known to occur after transplantation. This event seems to be related to the early hypoxia state that 286 
characterizes the post-grafting period [52]. However, this loss of dormant follicles is accompanied 287 
by an increase in the growing follicle population, suggesting a double mechanism of follicle death 288 
and activation [53]. The greatest concern about this method is safety of the procedure relating to 289 
that the replaced ovarian tissue might reimplant the cancer, therefore ovarian tissue should be 290 
properly inspected, both by histology and immunohistochemistry (with additional molecular 291 
analyses where possible) for malignant involvement of he ovarian tissue. This risk is however 292 
considered low in early breast cancer [5].  293 
 294 
Preimplantation genetic testing for monogenic disorder (PGT-M) to avoid BRCA 295 
transmission 296 
The mean age at diagnosis of breast cancer for BRCA1 and BRCA2 mutation carriers is 43 and 47 297 
years, respectively [96], but with a significant number of cases diagnosed before age 35. In BRCA1 298 
carriers, the cancer incidence per year is 10/1000 in women between 20 and 29 years, 17/1000 299 
between 30 and 39, and 20/1000 between 40 and 49 years. For BRCA2 carriers, the incidence peaks 300 
at age 40 to 49 (41/1000 cases per year) [54]. These women are therefore encouraged to undergo 301 
risk reducing salpingo-oophorectomy at ages 35-40 for BRCA1-carriers and between 40 and 45 for 302 
BRCA2-carriers [50]. PGT-M offers a valid option for BRCA-carriers women wishing to avoid 303 
transmission of the mutation to their offspring and being able to conceive an unaffected child. 304 
Preimplantation genetic testing in the human was successfully introduced in the late 1980s for 305 
fertile couples at risk of transmitting X chromosome-linked diseases to their children [35]. The 306 
process involves the aspiration of one or more cells from an embryo generated through IVF, 307 
subsequent genetic analysis, and the transfer into the uterus of only unaffected embryos [11, 35]. As 308 
stated earlier, the evolution of pre-implantation genetic assessment started with the analysis of 309 
limited number of chromosomes using the fluorescence i  situ hybridization (FISH) technology in 310 
the late 1980s [11, 35]. It was soon replaced by analysis of the whole chromosome set by using 311 
different genetic platforms, such as metaphase Comparative Genomic Hybridization (CGH), array 312 
based Comparative Genomic Hybridization (aCGH), single nucleotide polymorphism (SNP) 313 
microarray, and quantitative polymerase chain reaction (qPCR). At present, the most advanced 314 
technique is Next Generation Sequenzing (NGS), whiche refers to a DNA sequencing technology 315 
that enables sequencing of millions of small DNA fragments in unison. NGS has revolutionized 316 
genomic research studies, and is currently the goldstandard for the analysis of monogenic diseases 317 
or single single gene mutations [84]. As an autosomal dominant, women with a BRCA mutation 318 
have a 50% chance of transferring it to their offspring. BRCA1 and BRCA2 are members of the 319 
ATM (ataxia teleangiectasia mutation) protein family, involved in DNA double strand damage 320 
detections and repairs. Loss of ATM function in human and mouse causes defects in DNA repair 321 
and cell cycle checkpoint control and thus predisposes to cancers. BRCA1 is also highly expressed 322 
in germ cells and blastocysts, suggesting a possible role in gametogenesis and embryogenesis. In 323 
the oocytes of primordial follicles in BRCA mutation carriers, it has been suggested that DNA 324 
damage may accumulate over time: this may lead to loss of some follicles, with a reduction in the 325 
ovarian reserve. This correlation has been demonstrated in mice model, where BRCA1 mutation is 326 
associated with lower primordial follicle counts and AMH levels compared to normal controls [92] 327 
and there are data suggesting the same in women, for BRCA1 but not BRCA2 [65, 71, 92]. Women 328 
with BRCA mutations may show a reduced ovarian respon e to OS [46] although not all studies 329 
have confirmed this [85]. With the PGT-M technique, embryos cultured in vitro are genetically 330 
tested for the presence of the mutation, in order to transfer only BRCA negative embryos to the 331 
uterus. Couples undergoing PGT-M are usually fertile but they have to undergo IVF treatment, 332 
which can be costly and stressful. These couples also have to face the possibility that all embryos 333 
might be affected, and that the transfer of an unaffected embryo may not lead to a successful 334 
pregnancy. In 2003, despite uncertainties about prospective improvements and therapeutic 335 
opportunity, the European Society of Human Reproduction and Embryology (ESHRE) ethics 336 
taskforce considered genetic testing acceptable for hereditary conditions and multifactorial diseases 337 
such as BC or other cancer dispositions [86]. A major benefit compared to the alternative approach 338 
of prenatal testing is the avoidance of consideration of termination of an otherwise viable 339 
pregnancy. It is important to recognize that PGT-M is not a therapy, but only a selection tool. As an 340 
autosomal dominant condition, half of the embryos will be expected to test positive for the relevant 341 
BRCA mutation and thus will be discarded. As the number of available embryos will decline with 342 
the woman’s age and the number of oocytes collected, it seems more appropriate only in young BC 343 
patients. As discussed above, being a carrier of a BRCA mutation may also reduce the number of 344 
embryos available for testing. Moreover, for PGT-M a physically demanding in vitro fertilization 345 
treatment is required regardless of couple’s fertility, and OS is necessary, which can delay cancer 346 
treatment [39, 40]. Opinion studies among women affected by BC have shown that the majority, 347 
after being informed about PGT-M, are in favour of offering PGT-M for BRCA1 and BRCA2 348 
mutations, although only a minority would consider this option for themselves [24, 67]. PGT-M for 349 
BRCA mutations is growing; a survey of 1081 BRCA mutation carriers highlighted that patients are 350 
keen to have reproductive counseling, with more than 50% stating that PGT-M should be offered. 351 
The most frequently quoted reason in considering PGT-M was, in all categories of couples, to 352 
protect their future child from the physical and psychological impact of the BRCA mutation [15].  353 
 354 
Conclusion  355 
FP is a rapidly developing area of medicine, and the provision of information to patients facing the 356 
loss of fertility throught treatment for cancer and other conditions has become standard of care. 357 
Women should be informed not only about advantages of oocyte and embryo cryopreservation, as 358 
established technology that will contribute to achieve a pregnancy after cancer, but also about the 359 
general risks, cost and effectiveness of the procedures to reach a shared decision. Reproductive 360 
decision-making regarding PGT-M is complex for BRCA mutation carriers. For some couples, the 361 
emotional impact of the decision is substantial and lo g-lasting, therefore reproductive and dynamic 362 
counselling over time is crucial, considering that a women’s aspirations may change with age. All 363 
women about to receive chemotherapy for a newly diagnosed BC should receiveprope r and 364 
complete oncofertility counselling regarding the possible gonadotoxic risk and potential approaches 365 
for FP, to allow them to take fully informed decisions about the proposed therapy and its long-term 366 
consequences. This requires as a minimum the developm nt of optimized communication between 367 
specialities, with referral to reproductive medicine clinics for ART becoming an integrated part of 368 
cancer care. The development of national and interna io al registries is required to monitor the 369 
techniques used, the success rates achieved and the long-term follow-up of children born from these 370 
procedures.  371 
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 33 
Figure 1: Potential targets of chemotherapeutic damage within the ovary. (A) Chemotherapeutic agents could 34 
be directly affecting the resting pool of primordial follicles or the growing follicle population. As growing 35 
follicles inhibit the recruitment of primordial follicles, the loss of this growing population will lead to 36 
increased activation of primordial follicles and so loss of that reserve. (B) Chemotherapeutic agents could be 37 
directly targeting the oocyte or the somatic cells. Oocyte death would result from death of the follicular 38 
somatic cells, as the oocyte is dependant on these for its survival. 39 
Reprinted with permission from Morgan et al, 2012 [45]. 40 
 41 
 42 
 43 
Figure 2. (A) Probability of pregnancy after cancer diagnosis in women with breast cancer (red) compared to 44 
matched population controls (blue). Table under the panel indicate the number of women at each 10 year 45 
interval. (B) Hazard ratio for first pregnancy after breast cancer diagnosis by period of diagnosis.  46 
Reprinted from Anderson et al, 2018 [4], with permission. 47 
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Table 1: Compares IVF outcomes in cancer patients versus non cancer patients 65 
 66 
 67 
Studies Number of 
Patients 1 
  
% Breast 
Cancer 2 
Mature Oocytes 3 Fertilized 2 PN 
 
Cardozo et al. [14] 
 
 
63 
 
41 (65%) 
Cancer 
12.4 
       
  Control 
10.9 
Cancer 
6.6 
Control 
7.1 
 
Domingo et al. [26] 208 142 (69%) 10.5 12.4 N/A N/A 
 
Knopman et al. [42] 
    
26 
   
10 (38%) 
 
14 
 
12 
 
 
N/A 
 
 
 
 
N/A 
Michaan et al. [57] 22 12 (55%) 8.8 8.8 5.4 5 
Robertson et al. [79] 38 16 (42%) 12 14 6 7 
Quintero et al. [76] 50 28 (56%) 11.5 13 6.8 7.4 
Johnson et al. [37] 50 29 (58%) 12.4 11.7 5.4 6 
 68 
1 Number of cancer patients included in trial 69 
 70 
2 Number and percentage of breast cancer patients included in study 71 
 72 
3 Mean number of oocytes collected for cancer patients and control patients. 73 
 74 
 75 
 76 
 77 
